Niki BioSolutions said on October 16, 2026, that its Rett biomarker program had been featured in the International Rett Syndrome Foundation’s “Rett Research Tool Belt” series. Developed by wholly owned subsidiary DiamiR Biosciences, the blood-based panel is intended to help researchers monitor disease progression and potential treatment response, but those uses remain under investigation.
Key Takeaways
- The foundation’s feature highlights DiamiR’s blood-based panel of 44 microRNAs.
- Two human studies evaluated samples from more than 200 people with and without Rett syndrome.
- Researchers want to track biomarker changes over time; the feature does not establish validated treatment-response monitoring.
Table of Contents
- What the Rett biomarker program measures
- Research visibility, not a new clinical milestone
- Long-term sampling is the next research objective
- Conclusion
What the Rett biomarker program measures
DiamiR’s approach measures microRNAs, small molecules involved in regulating gene expression, in blood plasma. The panel includes molecules enriched in the brain and other organs affected by Rett syndrome, rather than focusing on the brain alone.
IRSF’s October 15 research feature describes two proof-of-concept studies in which researchers found patterns that distinguished people with Rett from age-matched controls and identified differences among Rett subgroups. Those findings suggest possible research uses, but do not by themselves establish that the panel can reliably monitor progression or treatment effects.
| Item | Details |
|---|---|
| Listed company | Niki BioSolutions, Nasdaq ticker NIKI |
| Study collaborators | Montefiore Medical Center and Albert Einstein College of Medicine |
| Foundation series | Six complementary research areas, including biomarkers and long-term tracking |
Research visibility, not a new clinical milestone
The immediate development is the program’s inclusion in the foundation’s educational research series. Niki’s announcement did not disclose new study results, a regulatory decision or a commercial launch.
Niki Chief Operating Officer and President Alidad Mireskandari said the company believes objective, minimally invasive biomarkers could become useful for evaluating disease severity, progression and treatment response as therapies advance through clinical development. That is a prospective application, not an established outcome.
The practical aim is to complement observations of symptoms and abilities with biological measurements. Repeated blood sampling could potentially help researchers detect changes that are not yet apparent in clinical assessments.
Long-term sampling is the next research objective
Kira Sheinerman, DiamiR’s co-founder and a Niki director, described an ambition to collect follow-up samples from people whose baseline samples were taken several years earlier. Comparing samples from the same individuals could help researchers assess whether microRNA patterns change alongside Rett progression.
The team also wants to investigate relationships between specific MECP2 variants and microRNA signatures. Sheinerman said there is not yet enough information to draw conclusions about those relationships. The feature did not provide a timetable for the proposed longitudinal work.
Conclusion
The foundation feature gives Niki’s program greater visibility within Rett research, without changing its investigational status. The next research question is whether repeat sampling can connect microRNA changes with disease progression; no completion date was announced.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
